Last reviewed · How we verify
NCT06581796
Pepsinogen-1 Serum Levels in Hyperemesis Gravidarum
trial testing pepsinogen-1 in Hyperemesis Gravidarum in 40 participants. Completed in 21 November 2024.
10 September 2024
Quick facts
| Lead sponsor | Ankara Etlik City Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 July 2024 |
| Primary completion | 10 September 2024 |
| Estimated completion | 21 November 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- pepsinogen-1
Conditions studied
- Hyperemesis Gravidarum — all drugs for Hyperemesis Gravidarum →
- Pregnant With Complication — all drugs for Pregnant With Complication →
Sponsor
Ankara Etlik City Hospital
Who can join
Adults 21 to 35, female only, with Hyperemesis Gravidarum or Pregnant With Complication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators planned to investigate maternal serum pepsinogen-1 (MSPG-1) levels in pregnant women with severe hyperemesis gravidarum (HG) and pregnant women without severe HG. HG is the most common cause of hospitalization in the first trimester of pregnancy and represents an economic burden on the healthcare system. Therefore, our aim in this study was to investigate whether there is a statistical difference in MSPG-1 levels between pregnant women with severe HG and pregnant women without severe HG and to determine a cut-off value for MSPG-1 levels for the indication of hospitalization of pregnant women with HG. The study poses no risk to the pregnant woman or the fetus.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Maternal serum pepsinogen-1 levels in severe hyperemesis gravidarum and the need for hospitalization: a prospective study.
Sucu S, Firatligil FB, Kurt A, Dereli ML, et al · · 2026 · PMID 41776488 · DOI 10.1186/s12884-026-08887-8
Verify or expand the search:
- PubMed search for NCT06581796
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperemesis Gravidarum
Currently open trials in the same condition.
- NCT06615843 — Randomized Study of a Dematerialized Management for Post-Emergency Gynecological Follow-Up · NA · recruiting
Other Ankara Etlik City Hospital trials
Trials by the same sponsor.
- NCT07472452 — MULTIMODAL APPROACH IN THE DIAGNOSIS OF SEPTIC AKI · not yet recruiting
- NCT07488442 — Efficacy of Cognitive Behavioral Therapy Administered in Patients With Dyssynergic Defecation · NA · recruiting
- NCT07488455 — Effectiveness of Video-Based or Written Pelvic Floor Education in Postpartum Women · NA · recruiting
- NCT07375173 — ORI-Guided FiO₂ Titration in Prone Spine Surgery: Impact on Postoperative Atelectasis Assessed by Lung Ultrasound · NA · not yet recruiting
- NCT07456202 — Menstrual Status, Anesthetic Consumption, and PONV · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06581796 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara Etlik City Hospital
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06581796.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing